کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5524158 1546248 2016 12 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia
ترجمه فارسی عنوان
تزریق داخل سلول قلب طبیعی دونر بعد از پیوند سلول های هتروپوئیتی لکوستیک انسانی لکوستیک انسانی در بیماران مبتلا به لوسمی حاد
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی


- Early additional donor natural killer cell infusion after HLA-haploidentical hematopoietic cell transplantation is not associated with an enhanced antileukemia effect
- Early donor natural killer cell infusion after HLA-haploidentical hematopoietic cell transplantation is associated with significant toxicities related to cytokine release
- Higher NKp30 expression on donor natural killer cells is an independent predictor for higher complete remission and less leukemia progression after HLA-haploidentical hematopoietic cell transplantation and donor natural killer cell infusion

The optimum method of donor natural killer cell infusion (DNKI) after allogeneic hematopoietic cell transplantation (HCT) remains unclear. Fifty-one patients (age range, 19 years to 67 years) with refractory acute leukemia underwent HLA-haploidentical HCT and underwent DNKI on days 6, 9, 13, and 20 of HCT. Median DNKI doses were .5, .5, 1.0, and 2.0 × 108/kg cells, respectively. During DNKI, 33 of the 45 evaluated patients (73%) developed fever (>38.3°C) along with weight gain (median, 13%; range, 2% to 31%) and/or hyperbilirubinemia (median, 6.2 mg/dL; range, 1.0 mg/dL to 35.1 mg/dL); the toxicity was reversible in 90% of patients. After transplantation, we observed cumulative incidences of neutrophil engraftment (≥500/µL), grade 2 to 4 acute graft-versus-host disease (GVHD), chronic GVHD, and nonrelapse mortality of 84%, 28%, 30%, and 16%, respectively. The leukemia complete remission rate was 57% at 1 month after HCT and 3-year cumulative incidence of leukemia progression was 75%. When analyzed together with our historical cohort of 40 patients with refractory acute leukemia who underwent haploidentical HCT and DNKI on days 14 and 21 only, higher expression of NKp30 (>90%) on donor NK cells was an independent predictor of higher complete remission (hazard ratio, 5.59) and less leukemia progression (hazard ratio, .57). Additional DNKI on days 6 and 9 was not associated with less leukemia progression (75% versus 55%).

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Biology of Blood and Marrow Transplantation - Volume 22, Issue 11, November 2016, Pages 2065-2076
نویسندگان
, , , , , , , , , , , , , , , , , ,